Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
- Revenue increased 16.1% YoY to $0.6 million
- Operating costs decreased 13.7% YoY to $1.5 million
- Strategic partnership with PeriNess Ltd. for clinical studies
- Completed preliminary preclinical studies with positive data across several cancer indications
- Net loss of $0.9 million in Q1 2025
- Departure of former CEO and Chief Scientific Officer in Q2 2024
- Limited cash position of $5.2 million for operations
Insights
Xenetic reports mixed Q1 with stable cash position while advancing cancer treatment collaborations, though revenue growth doesn't offset continued losses.
Xenetic Biosciences reported
The company ended Q1 with
The most significant clinical progress centers on Xenetic's DNase I platform, which is being positioned for multiple cancer indications with high unmet needs. Their collaboration with PeriNess to evaluate DNase for relapsed/refractory osteosarcoma and Ewing sarcoma represents an expansion beyond their initial focus on pancreatic carcinoma. Additionally, preliminary preclinical work combining DNase I with chemotherapy, immunotherapies, and CAR-T therapy in colorectal cancer models has been completed.
Xenetic's strategic pivot toward investigator-initiated studies with institutional partners reflects a pragmatic approach for a small biotech. This model allows them to generate valuable clinical data while conserving resources, potentially creating value inflection points without the full financial burden of traditional clinical trials. However, the company still faces the fundamental challenge of translating promising preclinical results into clinical success, particularly in difficult-to-treat cancers where historical success rates remain low.
Strategic focus on exploratory investigator-initiated clinical studies with institutional partners
Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma
Ended the quarter with
FRAMINGHAM, MA / ACCESS Newswire / May 14, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2025.
Recent Highlights
Announced that its collaboration partner, PeriNess Ltd., entered into a Clinical Study Agreement to advance development of DNase platform for the treatment of relapsed/refractory osteosarcoma and Ewing sarcoma; and
Continued pursuit of other strategic collaborations to advance the Company's technology.
"We remain focused on engaging with our strategic partners to participate in a series of exploratory studies to evaluate our systemic DNase I in combination with immunotherapy, chemotherapy, and radiotherapy in various oncology indications where there remains significant unmet need to advance our development programs forward. These partnerships allow us to advance our technology toward the clinic while utilizing our resources efficiently and minimizing our internal investment. Additionally, this development strategy opens up valuable opportunities to continue expanding our growing body of positive preclinical data that supports the use of DNase I across several cancer indications," commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.
Xenetic continues to advance its DNase-based technology towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. Preliminary preclinical studies evaluating the combinations of DNase I with chemotherapy and DNase I with immuno-therapies in colorectal cancer models as well as CAR-T therapy have been completed.
Additionally, as previously announced in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator initiated studies of recombinant DNase as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.
Summary of Financial Results for First Quarter 2025
Net loss for the quarter ended March 31, 2025 was approximately
The Company ended the quarter with approximately
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues" and other words of similar meaning, including, but not limited to, all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our focus on exploratory investigator-initiated clinical studies with institutional partners, our strategic collaborations, including expectations under our Clinical Trial Services Agreement with PeriNess regarding certain investigator initiated studies of recombinant DNase in Israeli medical centers, our overall development strategy, our continued pursuit of other strategic collaborations to advance the Company's technology, our focus on leveraging strategic partners to advance out technology toward the clinic, our commitment to the DNase program, our expectations regarding further expansion of our body of clinical data, our focus on advancing innovative immune-oncology technologies addressing difficult to treat cancers, the DNase technology improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the Clinical Trial Services Agreement with PeriNess; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase technologies; (5) the ability of the Company to obtain funding and implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What were XBIO's Q1 2025 financial results?
What is Xenetic Biosciences' main development focus in 2025?
How much cash does XBIO have on hand in Q1 2025?
What strategic partnerships does XBIO have for its clinical studies?
What management changes occurred at Xenetic Biosciences?
